Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
술파디아진
설파다이아진 · 술파디아진 · 설파디아진 · SULPHADIAZINE · SULFADIAZIN · Sulfadiazine,(S) · Sulfadiazene · Diazin
식별자 및 물리적 특성
| CAS No. | 68-35-9 |
|---|---|
| 분자식 | C10H10N4O2S |
| 평균 분자량 | 250.28 g/mol |
| 단동위원소 질량 | 250.05244656 g/mol |
| SMILES | Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1 |
| InChIKey | SEEPANYCNGTZFQ-UHFFFAOYSA-N |
| PubChem CID | 5215 |
| ChEMBL | CHEMBL439 |
| ChEBI | CHEBI:9328 |
| EC No. | 200-685-8 |
| DTXSID | DTXSID7044130 |
| 현지명 | 술파디아진 |
화학 및 물리적 성질
| XLogP | -0.1 |
|---|---|
| 극성 표면적 | 106 |
| 수소 결합 공여자 수 | 2 |
| 수소 결합 수용자 수 | 6 |
| 회전 가능 결합 수 | 3 |
| 무거운 원자 수 | 17 |
| 형식 전하 | 0 |
| 복잡도 | 327 |
| 의약품 | Pharmaceuticals -> Antibiotics (Sulfonamide)Pharmaceuticals -> AntibioticsPharmaceuticals -> Listed in ZINC15 |
| SpringerMaterials Properties | Fusion temperature |
| LogP(분배 계수) | -0.2-0.04 |
| 용해도 | 6.01e-01 g/L디메틸설폭사이드에 용해됩니다. |
| Human Drugs | FDA approved drugs -> Active ingredientAnti-infective medicines |
| Animal Drugs | Active Ingredients (Sulfadiazine) -> FDA GreenbookPharmaceuticals -> UK Veterinary Medicines Directorate ListPharmaceuticals -> Animal Drugs -> Approved in Taiwan |
| Physical Description | Solid |
| Dissociation Constants | 6.36 |
| Collision Cross Section | 153.9 Ų [M+H]+ [CCS Type: TWMethod: calibrated with Waters Major Mix]150.9 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]148.7 Ų [M+H]+ [CCS Type: TW]157.85 Ų [M+Na]+ [CCS Type: TW151.96 Ų [M+H]+ |
| 녹는점 | 253 °C (dec.) (lit.) |
| 끓는 점 | 512.6±52.0 °C(Predicted) |
| 밀도 | 1.3780 (rough estimate) |
| 굴절률 | 1.6440 (estimate) |
| 저장 조건 | 2-8°C |
| pKa(산도 계수) | pKa 2.21(H2O t = 25 I = 0.5 (NaCl)) (Uncertain) |
| 물리적 상태 | 가루 |
| 색상 | 하얀색 |
| 용해도 | 67.13mg/L(25℃) |
| Merck | 14,8903 |
| BRN | 6733588 |
| BCS Class | 4/3 |
| 주요 응용 | 임상 시험 |
| InChI | 1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14) |
| InChIKey | SEEPANYCNGTZFQ-UHFFFAOYSA-N |
| SMILES | Nc1ccc(cc1)S(=O)(=O)Nc2ncccn2 |
| NIST | Sulfadiazine(68-35-9) |
| EPA | Benzenesulfonamide, 4-amino-N-2-pyrimidinyl- (68-35-9) |
화학적 성질
White to slightly yellow crystalline pow
안전 및 규제
| GHS 분류 | This chemical does not meet GHS hazard criteria for 1.2% (2 of 171) of reports.DangerH302 (98.2%): Harmful if swallowed [Warning Acute toxicity, oral]P203, P233, P260, P261, P263, P264, P264+P265, P270, P271, P272, P273, P280, P284, P301+P317, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P330, P332+P317, P333+P317, P337+P317, P342+P316, P362+P364, P391, P403, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 171 reports by companies from 21 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| 규제 정보 | Status: Active Update: 23-04-2018 https://echa.europa.eu/registration-dossier/-/registered-dossier/17511Sulphadiazine: Does not have an individual approval but may be used under an appropriate group standard |
| 기타 안전 정보 | IMAP assessments - Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-: Environment tier I assessment |
| Hazard Classes and Categories | Acute Tox. 4 (98.2%) |
| Hepatotoxicity | Sulfadiazine, like other sulfonamides, causes a characteristic idiosyncratic liver injury which has features of drug-allergy or hypersensitivity. The typical onset is sudden development of fever and rash followed by jaundice within a few days or weeks of starting the medication. The pattern of injury is typically mixed, although fatal cases are often hepatocellular and prolonged cholestatic cases have also been described. Eosinophilia or atypical lymphocytosis are also common and the clinical pattern can be considered a part of DRESS syndrome (drug rash with eosinophilia and systemic symptoms). Cases of Stevens Johnson syndrome due to sulfadiazine have also been described. Sulfonamides such as sulfadiazine have been linked to many cases of acute liver failure and as a class, the sulfonamides still rank in the top 5 to 10 causes of drug induced, idiosyncratic fulminant hepatic failure. However, most cases of sulfonamide induced liver injury resolve rapidly, usually within 2 to 4 weeks unless cholestasis is severe. Onset of injury is more rapid with rechallenge and can appear within a day or reexposure. Patients with hepatic injury due to sulfadiazine may have a history of previous exposure to the drug without injury. Sulfonamides such as sulfadiazine can also cause mild and transient ALT elevations that do not progress to jaundice or more severe liver injury either alone or as a part of a generalized hypersensitivity reaction. Sulfonamides have also been linked to hepatic granulomas. |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)SulfadiazinevLess-DILI-concern3Adverse reactionsDOI:10.1016/j.drudis.2016.02.015 |
| 수질 위해 등급(WGK) | 3 |
| TSCA 등재 상태 | TSCA listed |
| RTECS 번호 | WP1925000 |
| 운송 번호(UN) | 3249 |
| 독성 | LD50 oral in mouse: 1500mg/kg |
| 관세 코드 | 29335990 |
| 위험 문구(R) | 22-36/37/38-42/43-43-42 |
| 위험 표시 | Xn,Xi |
| 안전 문구(S) | 26-36 |
| 포장분류 | III |
| 위험 등급 | 6.1(b)Acute Tox. 4 OralAquatic Chronic 2Repr. 2 |
| 기존화학 물질 | KE-01586 |
| F 고인화성물질 | 10 |
| 저장 분류 | 11 - Combustible Solids |
용도
용도
It is used in the form of silver salts (sulfadiazine silver) as an external antibacterial agent, primarily for treating burns. It is believed that the presence of the silver ion in the molecule facilitates increased antimicrobial and wound-healing action.
일반 설명
Sulfadiazine’s plasma half-life is 17 hours. It is a white,odorless crystalline powder soluble in water to the extentof 1:8,100 at 37°C and 1:13,000 at 25°C, in human serumto the extent of 1:620 at 37°C, and sparingly soluble in alcoholand acetone. It is readily soluble in dilute mineralacids and bases. Its pKa is 6.3.